Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
| ▸ | KCNN4 | O15554 | 8/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1629941 | 0.87 | HSP90AA1 (0.67) | HSP90AA1SMN1; SMN2NR3C2MAPK14PDE10A | |
| SCHEMBL1630437 | 0.87 | HSP90AA1 (0.67) | HSP90AA1SMN1; SMN2NR3C2MAPK14PDE10A | |
| SCHEMBL1631608 | 0.81 | HSP90AA1 (0.72) | HSP90AA1SMN1; SMN2NR3C2MAPK14KCNN4 | |
| SCHEMBL1629137 | 0.81 | HSP90AA1 (1.00) | HSP90AA1SMN1; SMN2NR3C2MAPK14KCNN4 | |
| SCHEMBL1630519 | 0.81 | HSP90AA1 (0.60) | HSP90AA1SMN1; SMN2NR3C2MAPK14PDE10A | |
| SCHEMBL626539 | 0.78 | KCNN4 (0.55) | HSP90AA1SMN1; SMN2NR3C2MAPK14KCNN4 | |
| SCHEMBL13522945 | 0.77 | HSP90AA1 (0.51) | HSP90AA1NR3C2IDO1KDM4E | |
| SCHEMBL1629661 | 0.76 | HSP90AA1 (0.65) | HSP90AA1SMN1; SMN2NR3C2MAPK14PDE10A | |
| SCHEMBL14696701 | 0.76 | HSP90AA1 (0.54) | HSP90AA1SMN1; SMN2NR3C2MAPK14KCNN4 | |
| SCHEMBL1629098 | 0.76 | HSP90AA1 (0.63) | HSP90AA1SMN1; SMN2NR3C2MAPK14PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130317212-A1 | LIGHT EMITTING MATERIALS FOR ELECTRONICS | SOLVAY SA (BE) | 2013-11-28 | — | — | US | disclosed |
| EP-2603515-A1 | LIGHT EMITTING MATERIALS FOR ELECTRONICS | SOLVAY SA (BE) | 2013-06-19 | — | — | EP | disclosed |
| CN-103068833-A | Light emitting materials for electronics | SOLVAY | 2013-04-24 | — | — | CN | disclosed |
| EP-2423214-A1 | Light emitting materials for Electronics | Solvay SA (BE) | 2012-02-29 | — | — | EP | disclosed |
| EP-2423214-A1 | Light emitting materials for Electronics | Solvay SA (BE) | 2012-02-29 | — | — | EP | disclosed |
| WO-2012019948-A1 | LIGHT EMITTING MATERIALS FOR ELECTRONICS | SOLVAY SA (BE) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012019948-A1 | LIGHT EMITTING MATERIALS FOR ELECTRONICS | SOLVAY SA (BE) | 2012-02-16 | — | — | WO | disclosed |
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | HSP90AA1 1213/4885SMN1; SMN2 4633/4885NR3C2 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.